Article Information
vol. 28 no. 152
PubMed
Published By
Print ISSN
Online ISSN
History
- Received May 17, 2019
- Accepted June 25, 2019
- Published online July 8, 2019.
Copyright & Usage
Copyright ©ERS 2019. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Author Information
- Ian Pavord1,
- Thomas Bahmer2,
- Fulvio Braido3,
- Borja G. Cosío4,5,
- Marc Humbert6,7,
- Marco Idzko8 and
- Lukasz Adamek9⇑
- 1Nuffield Dept of Medicine and Oxford Respiratory NIHR BRC, University of Oxford, Oxford, UK
- 2Dept of Internal Medicine, University Hospital Schleswig-Holstein, Kiel, Germany
- 3Dept of Internal Medicine, Respiratory Diseases and Allergy, University of Genoa, Ospedale Policlinico IRCCS San Martino, Genoa, Italy
- 4Hospital Universitario Son Espases, Palma, Spain
- 5Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain
- 6Faculté de Médecine, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France
- 7Service de Pneumologie, Centre de Référence de l'Hypertension Artérielle Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
- 8Dept of Pulmonary Medicine, University Hospital Freiburg, Freiburg, Germany
- 9AstraZeneca, Luton, UK
- Lukasz Adamek, AstraZeneca, 600 Capability Green, Luton, LU1 3LU, UK. E-mail: lukasz.adamek{at}astrazeneca.com
Funding
AstraZeneca
Article usage
Altmetrics
Vol 28 Issue 152
Table of Contents
Severe T2-high asthma in the biologics era: European experts' opinion
Jump To
- Article
- Abstract
- Abstract
- The era of biologics for airways disease: where are we now?
- Management of severe asthma with currently available biological therapies
- Is it possible to recognise severe asthma earlier?
- Monitoring treatment response and addressing the lack of adherence to medication
- Initiating biological therapies
- Acknowledgements
- Footnotes
- References
- Figures & Data
- Info & Metrics